Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment
Graham H. Bothamley (London, United Kingdom), Graham H. Bothamley, Christoph Lange
|   |
Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes
Yana Batyrshina (Novosibirsk, Russian Federation), Yana Batyrshina
|  |
Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD)
Sachin Kumar (Bangalore, India), Sachin Kumar, Naveen Kumar, Shiv Sarin
| |
Use of delamanid for M/XDR-TB treatment under programmatic conditions in Latvia
Linda Barkane (Riga, Latvia), Linda Barkane, Liga Kuksa, Gunta Kirvelaite, Zita Lauska, Vaira Leimane
| |
Steps of bedaquline implementation in Georgia
Nana Kiria (Tbilisi, Georgia), Nana Kiria, Zaza Avaliani, Lali Mikiashvili
| |
Compassionate use of bedaquiline in a cohort of Indian drug resistant tuberculosis(DR-TB) patients
Jai Mullerpattan (Mumbai, India), Zarir Udwadia, Jai Mullerpattan, Shashank Ganatra, Rohit Amale
| |
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety
Sergey Borisov (Moscow, Russian Federation), Sergey Borisov, Alexsey Filippov, Taisiya Ivanushkina, Diana Ivanova, Nataliya Litvinova
| |